Program
nelitolimod
Also written as “SD-101”, “SD-101 Dermal Cream (6%)” and “SD-101-6.0 cream”.
Its studies are mostly in Epidermolysis Bullosa · Carcinoma, Hepatocellular · Uveal Melanoma · Melanoma · Lymphoma, B-Cell, led by 5 companies.
Drug pageNelitolimod: every studyMany companies study it; this page follows only the 14 they lead. All 25 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioMarin Pharmaceuticalits history only | 40 open or running | phase 3since Feb 13, 2015 | Dec 12, 2013 | none ahead |
| Sanofiits history only | 40 open or running | phase 2since Oct 13, 2014 | Jan 11, 2008 | none ahead |
| TriSalus Life Sciencesits history only | 31 open or running | phase 2since Jan 21, 2022 | Jun 2, 2021 | Sep 2027phase 1 · NCT05607953 |
| Paradigm Therapeuticsits history only | 22 open or running | phase 3since Mar 4, 2026 | Mar 4, 2026 | May 17, 2027phase 3 · NCT07482787 |
| Merck | 10 open or running | phase 1since Apr 4, 2016 | Apr 4, 2016 | none ahead |
Also a collaborator on its studies: Synteract and PPD DEVELOPMENT, LP.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Apr 4, 2016First study: phase 1 study in NeoplasmsFirst studyNCT02731742 · 14 enrolled
- Aug 11, 2024Named nelitolimodINNProposed as its International Nonproprietary Name in WHO's List 131 · before, SD-101
TargetBeta
“A class C CpG-oligodeoxynucleotide (ODN) agonist of toll-like receptor 9 (TLR9), with immunostimulatory, immunoadjuvant and antineoplastic activities”NCIt, by rule
Studies
The one study Merck leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02731742Neoplasms | 1 | Terminated | Jan 8, 2018 | 14 |
How it is read
Names in the registry
- “SD-101”, 7 entries
- “SD-101 Dermal Cream (6%)”, 3 entries
- “SD-101-6.0 cream”, 2 entries
- “SD-101(1)”, 1 entry
- “SD-101(2)”, 1 entry
Conditions, from the studies’ own filings
- Epidermolysis Bullosa, 6 studies
- Carcinoma, Hepatocellular, 1 study
- Uveal Melanoma, 1 study
- Melanoma, 1 study
- Lymphoma, B-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.